A cute heart failure (AHF) is a major and growing health issue in developed countries. It is the leading cause of hospitalization, involving more than 1 million people hospitalized each year in the Unites States, as well as in Europe. 1 Given the high rates of in-hospital mortality 2, 3 and postdischarge re-hospitalization or death, 4 a prompt strategy for risk stratification and subsequently tailored therapy would be helpful to improve clinical outcomes. The Seattle Heart Failure Model 5 and the Heart Failure Survival Score 6 were validated to predict survival and prognosis in patients with heart failure. However, the complexity of these scoring systems has dampened the applications in clinical practice. Spinar et al 7 recently developed the AHEAD (A: atrial fibrillation; H: hemoglobin; E: elderly; A: abnormal renal parameters; D: diabetes mellitus) scoring system as a simple, bedside clinical prognostic model in a multicenter prospective registry of AHF, involving 5846 patients. Based on age and comorbidities, each 1-point increase of AHEAD score was associated with %10% excessive 1-year mortality. However, whether there are discrepancies or not, the prognostic values of the AHEAD score in different phenotypes of AHF remains to be elucidated.
We therefore investigated the clinical significance of the AHEAD score to predict long-term prognosis in an Asian AHF cohort comprising AHF subjects with either reduced or preserved left ventricular ejection fraction (HFrEF or HFpEF).
Methods Study Population
The study population was drawn from the heart failure registry of Taipei Veterans General Hospital (HARVEST registry) that included patients hospitalized for AHF, defined as new-onset or gradually or rapidly worsening heart failure symptoms and signs requiring urgent therapy. Consecutive AHF patients with New York Heart Association functional class III or IV symptoms, compatible presentations of chest radiograph, and responses to diuretics, were enrolled. 8, 9 Subjects with acute coronary syndrome, severe hepatic disease, or severe infection were excluded from this analysis. In a total of 2663 eligible subjects hospitalized primarily for AHF from October 2003 to December 2012, 2143 patients with complete data of hematology, biochemistry, and echocardiogram constituted this study population. The investigation conformed with the principles outlined in the Declaration of Helsinki and was approved by the institutional review board of Taipei Veterans General Hospital. Given the nature of an administrative registry, informed consents were waived.
Definition and Covariates
AHEAD score was calculated by assigning 1 point for each of A: atrial fibrillation, H: hemoglobin <130 g/L for men and 120 g/L for women, E: elderly (age >70 years), A: abnormal renal parameters (creatinine >130 lmol/L), and D: diabetes mellitus. 7 Left ventricular ejection fraction (LVEF) was measured by 2-dimensional-guided M-mode echocardiogram. 10 Patients with a LVEF of 50% or higher were defined as HFpEF, whereas those with a LVEF of less than 50% were defined as HFrEF. Hemogram, renal function, serum electrolytes, and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured immediately upon presentation to the hospital. Uric acid and the lipid profiles were obtained at fasting the next morning. Estimated glomerular filtration rate was then calculated using the modified glomerular filtration rate estimating equation for Chinese patients. 11 Comorbidities were identified by medical history and the associated measures during the index hospitalization. Therefore, atrial fibrillation was diagnosed based on past or ad-hoc ECGs. Diabetes mellitus was confirmed by medical records and a glycosylated hemoglobin ≥6.5% during the index hospitalization. Hypertension was defined according to medical records. Renin-angiotensin system inhibitors were referred to either angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists. Given that the commercialized measurement of NT-proBNP (Roche Diagnostics, Basel, Switzerland) was available only after 2009, some patients had missing NT-proBNP data in this analysis.
The clinical end point was the occurrence of all-cause mortality or cardiovascular death. Mortality in the study population was ascertained by the International Classification of Diseases, 9
th Revision coding in the National Death
Registry with a follow-up duration of up to 3 years. Along with the increasing AHEAD score, patients were older, had more diabetes mellitus and atrial fibrillation, and had lower hemoglobin, estimated glomerular filtration rate, and total and low-density lipoprotein cholesterol, but higher creatinine and NT-proBNP levels (Table 1) . LVEF, prevalence of hypertension, and uric acid levels were also significantly different between patients with various AHEAD scores. In addition, subjects with de novo heart failure tended to have lower AHEAD scores. The prescriptions of b-blockers, mineralocorticoid antagonists, and statins, but not renin-angiotensin system inhibitors were significantly different among patients with various AHEAD scores.
Prognostic Values of AHEAD Score
During a mean follow-up duration of 22AE14 months, 838 patients (39%) died and 375 patients (18%) died of cardiovascular causes. Kaplan-Meier survival curve analysis demonstrated a significantly increased mortality along with an increase in AHEAD score in the total study population and in Table 1 . Baseline Characteristics, Stratified by AHEAD Score Variable AHEAD Score
Male sex, n (%) 47 (39) 190 (50) 351 (54) 474 (69) 329 (72) 58 (67) 0.121
HFrEF, n (%) 41 (64) 137 (46) De novo heart failure, n (%) 17 (27) 83 (28) 112 (21) 145 (21) 76 (17) 12 (14) 0.003 Table 2 ).
Refinement of AHEAD Score
Based on the multivariate Cox proportional hazard models, uric acid was independently related to clinical outcomes in the study population (Table 3) . By a cut-off value of 8.6 mg/dL derived from receiver operating characteristic curve analysis, uric acid was incorporated with the AHEAD score to construct the AHEAD-U index. 
Validation of the AHEAD-U Score
The baseline characteristics of the validation cohort, comparing to the study population, are demonstrated in Table 5 . Although the validation cohort was distinct from the study population, regarding age, left ventricular systolic function, and morbidities, the survival probabilities of the validation population were reduced when every 1-point increase of the AHEAD-U score ( Figure 3 ). The AHEAD-U score was crudely associated with total mortality during a 3-year follow-up duration (1.46, 1.21-1.76).
With adjustments for age and sex, AHEAD-U remained related to the outcomes (1.25, 1.01-1.56) of the validation cohort. The risk thresholds of 20% and 45% for all-cause mortality, and 10% and 23% for cardiovascular mortality were used to classify subjects as low-, moderate-, and high-risk group. eGFR indicates estimated glomerular filtration rate; HARVEST, heart failure registry of Taipei Veterans General Hospital; HFrEF, heart failure with reduced left ventricular ejection fraction; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; MRAs, mineralocorticoid antagonists; NT-proBNP, N-terminal prohormone brain natriuretic peptide; RAS, reninangiotensin system. *NT-proBNP were log-transformed.
Discussion
The present study independently validated a simple and practical scoring system, obtained from bedside estimation; the AHEAD score was independently associated with the longterm prognosis in an Asian cohort of AHF. Both in subjects with HFrEF and HFpEF, AHEAD score remained related to mortality consistently. The study may extend the clinical applications of risk-predicting models in patients with HFpEF, while the established prognostic calculators were constructed based on study populations, in which the majority were HFrEF. Given that uric acid was correlated with clinical outcomes, independent of AHEAD score, AHEAD-U score was computed by the incorporation with uric acid. AHEAD-U outperformed AHEAD score in improving the risk classification in patients with AHF.
Risk Classifications in Acute Heart Failure
The use of validated multivariable risk scores to estimate the subsequent risk of mortality in hospitalized patients with AHF has been recommended in the 2013 American College of Cardiology Foundation/American Heart Association Guideline. 14 For patients hospitalized with AHF, the ADHERE (Acute Decompensated Heart Failure National Registry) Classification and Regression Tree Model is predictive of in-hospital mortality. 2 The EFFECT (Enhanced are predictive of the longest 1-year mortality. In comparison with these published models, Spinar et al 7 demonstrated that the AHEAD risk scoring system is simpler and easier to obtain, based on comorbidities and bedside estimations. The value of the prognostic model is that of the information related to heart failure prognosis and disease trajectory, which may favorably influence physician-prescribing behaviors. Unlike CHA 2 DS 2 -Vasc score for atrial fibrillation, the existing HF prediction models are usually too complicated to be popularized. A simple model to predict the mortality of acute heart failure may facilitate the clinical applications at the bedside and finally improve the quality of care. The study confirmed that the AHEAD risk scoring system could be generalized to an Asian cohort by showing that each 1-point increment of the AHEAD score was associated with a 38% excessive 3-year mortality risk. However, given a higher LVEF and the exclusion of patients with acute coronary syndrome, the study population indeed had better survival, compared with that of Spinar et al 7 (Table 6 ). is similar to those with HFrEF, the neurohormonal activation and pathophysiological heterogeneity indeed are different between the phenotypes of HF. 18 Therefore, the prediction model might vary. To our knowledge, this is the first study to describe risk models specifically for hospitalized patients with HFpEF and HFrEF. AHEAD score was independently predictive of mortality in both subjects with HFrEF and HFpEF. However, each increment of AHEAD score was associated with 55% and 25% increasing risks of death in HFrEF and HFpEF, respectively. The results may support a better performance of AHEAD score in patients with HFrEF, and the heterogeneous pathophysiology of HFpEF that subjects with HFpEF have is more strongly associated with noncardiovascular comorbidity and aging. 19, 20 In the adjusted Cox regression model, AHEAD
was still associated with all-cause and cardiovascular mortality in subjects with either HFrEF or HFpEF, indicating the AHEAD score was still a prognostic factor in both phenotypic HF. Given the limited sample size (n=494) and events (135 mortalities and 54 cardiovascular deaths, respectively) in the fully adjusted model with NT-proBNP, we did not have sufficient power to evaluate the prognostic impacts of AHEAD score in the fully adjusted model of HFpEF.
AHEAD-U Outperformed AHEAD Score in the Prediction of Outcomes
We previously have demonstrated that hyperuricemia was correlated with increased mortality, independent of traditional risk factors and NT-proBNP in patients hospitalized for AHF with either HFrEF or HFpEF. 8 In this study, uric acid remained correlated with all-cause mortality, independent of AHEAD score and comorbidities. We therefore incorporated hyperuricemia (uric acid >8.6 mg/dL) with the AHEAD score to construct the AHEAD-U index. The study results showed that the AHEAD-U index significantly outperformed the AHEAD index by reclassifying 19.7% of subjects appropriately for allcause mortality and 20.1% for cardiovascular mortality, which may suggest the AHEAD-U index is more appropriate for predicting long-term prognosis in an Asian AHF cohort.
Study Limitations
The study has some limitations. First, since we only enrolled subjects who had undergone echocardiographic examinations in the analysis, selection bias was not avoidable. While the biplane Simpson's method is suggested to evaluate LVEF, 21 we used 2-dimensional-guided M-mode measures in this study because the data derived from Simpson's method were not registered in our web-based system until 2010. However, in a total of 818 patients with available LVEF measured by Simpson's rule, the conclusions remained the same (Table 7) . Second, 520 patients have been excluded from this analysis. However, their baseline characteristics regarding age, sex, LVEF, and morbidities, and the rate of mortality or cardiovascular death were similar to the analyzed samples, which suggested the samples were representative of the study population. In addition, there were 1376 missing values of NTproBNP mainly (82%) because of the historical constraint that commercialized measurement of NT-proBNP was available only after 2009. Although there were discrepancies in age, presence of hypertension and atrial fibrillation, hemoglobin, and uric acid levels, the absence of NT-proBNP values was not associated with mortality (1.14, 0.98-1.33) in Cox proportional hazard model. Meanwhile, the absence of NT-proBNP values and the mortality rates have a similar trend over the study period. After adjusting for the fixed "year" effect, the absence of NT-proBNP values also was not associated with mortality in logistic regression analysis. The evidence supported that the absence of NT-proBNP values was because of the historical constraint and it was not related to the outcomes. Third, considering the clinical feasibility, some other parameters that are reported to correlate with the prognosis of AHF such as active cancer, body mass index, and chronic obstructive pulmonary disease were not included in the present prognostic modeling. 2, 22, 23 Fourth, we internally validated the AHEAD-U score for the long-term outcomes of AHF patients in a small population. Further studies of clinical practice are needed to confirm the feasibility and generalizability of AHEAD as well as AHEAD-U scores.
Conclusions
In conclusion, the AHEAD score performed well for predicting long-term mortality in the Asian AHF cohort with either HFrEF or HFpEF. In addition, the AHEAD-U score may further improve the risk stratification from the AHEAD score.
